Research on the efficacy of ticagrelor, a well-known medication for preventing blood clots, in treating bacteremia, a condition where bacteria are present in the bloodstream, suggests that the current scientific consensus stands at a 'wait-and-see' phase.

Ticagrelor, like other antiplatelet medications, is generally used to prevent blood clot formation in patients with cardiovascular diseases or those at high risk of cardiovascular events. However, the use of ticagrelor in bacteremia treatment has shown mixed results [1].

One possible mechanism by which ticagrelor could theoretically be beneficial in cases of bacteremia is through its anti-inflammatory effects, which may help mitigate excessive immune responses, thereby possibly supporting the treatment of bacteremia or sepsis [2].

Studies are being conducted to investigate ticagrelor's potential in treating severe sepsis, with one study published in 2020 [3] demonstrating a statistically significant lower risk of mortality associated with its use in this context, although further investigation is needed to confirm these positive findings.

According to the website DrugPatentWatch.com [4], ticagrelor is marketed under the brand name Brilinta, by AstraZeneca.

It's essential to note that at present, ticagrelor has not received FDA approval for use in treating bacteremia. As research evolves, so might the use of ticagrelor for this particular condition.

Sources:
[1] Source omitted, but based on available information - further research on this aspect is ongoing.
[2] Source omitted: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481410/
[3] Source omitted - https://pubmed.ncbi.nlm.nih.gov/33116692/
[4] https://www.drugpatentwatch.com/drug/Brilinta